Crosslinked hydrogel for immune checkpoint blockade delivery
AssigneesGeorgia Tech Research Corporation, University of Louisville Research Foundation, Inc.
InventorsAndres J. Garcia, Maria M. Coronel, Haval Shirwan, Esma S. Yolcu
Life of this patent
Estimating the term…
Abstract
Disclosed are PD-L1 presenting compositions. The compositions may be used to effect immunomodulation in a variety of contexts. The compositions may be used to decrease rates of transplant rejection, including pancreatic islet cell transplantation. The compositions are useful for the treatment of type 1 diabetes.
Claims20
A three-dimensional PD-L1 presenting composition comprising a hydrogel network conjugated to PD-L1 via a biotin/streptavidin complex, wherein the hydrogel is covalently bound to a plurality of biotin residues, the PD-L1 is conjugated to streptavidin;
- and wherein the composition further comprises an immunosuppressant.
Dependencies are inferred from the claim text.